Close

Intuitive Surgical (ISRG) Misses Q1 EPS by 9c, Slight Beat on Revenues

April 18, 2019 4:07 PM EDT

Intuitive Surgical (NASDAQ: ISRG) reported Q1 EPS of $2.61, $0.09 worse than the analyst estimate of $2.70. Revenue for the quarter came in at $973.7 million versus the consensus estimate of $973.43 million.

  • Worldwide da Vinci procedures grew approximately 18% compared with the first quarter of 2018, driven primarily by growth in U.S. general surgery procedures and worldwide urologic procedures.
  • The Company shipped 235 da Vinci Surgical Systems, an increase of 27% compared with 185 in the first quarter of 2018.
  • The Company grew its installed base to 5,114 systems as of March 31, 2019, an increase of 13% compared with 4,528 as of the end of the first quarter of 2018.
  • First quarter 2019 revenue of $974 million grew approximately 15% compared with $848 million for the first quarter of 2018.
  • First quarter 2019 GAAP net income was $307 million, or $2.56 per diluted share, compared with $288 million, or $2.44 per diluted share, for the first quarter of 2018.
  • First quarter 2019 non-GAAP* net income was $312 million, or $2.61 per diluted share, compared with $288 million, or $2.44 per diluted share, for the first quarter of 2018.
  • In February 2019, the Company received U.S. Food and Drug Administration (“FDA”) clearance for the IonTM endoluminal system, the Company’s new flexible robotic-assisted catheter-based platform, designed to navigate through very small lung airways to reach peripheral nodules for biopsies.
  • In February 2019, the Company received FDA clearance for the IRISTM augmented reality product, designed to aid surgeons in both pre- and intra-operative settings by delivering a 3D image of the patient anatomy.
  • In March 2019, the Company received FDA clearance for the da Vinci SP® Surgical System for use in certain transoral otolaryngology procedures in adults.

For earnings history and earnings-related data on Intuitive Surgical (ISRG) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Earnings

Related Entities

Earnings, FDA